Crinetics Pharmaceuticals (CRNX) Financials

Crinetics Pharmaceuticals (NASDAQ: CRNX) continues to look like a classic late-stage biotech story: the company has a very large cash and investment position, but it is still generating significant operating losses as it funds research and development. The latest quarter shows meaningful balance-sheet strength, yet the income statement and cash flow statement still reflect heavy spending and negative operating cash flow.

What stands out most in Q1 2026: Crinetics reported $10.7 million in revenue, but operating expenses totaled $150.9 million, driving an operating loss of $140.4 million and a net loss of $127.8 million. The company ended the quarter with $1.29 billion in cash and short-term investments, which gives it substantial flexibility to keep advancing its pipeline.

• Cash and short-term investments totaled about $1.29 billion at the end of Q1 2026, giving the company a very strong liquidity cushion.
• Total current assets were $1.32 billion, while total liabilities were only $120.7 million, indicating a very conservative balance sheet.
• The company’s equity base remains large at $1.28 billion, supported by its cash-rich position.
• Interest and investment income of $12.7 million helped offset some of the operating losses.
• Operating revenue improved sharply versus the prior quarter, rising to $10.7 million from $6.2 million in Q4 2025 and from very small levels in earlier periods.
• The company continues to rely heavily on investment income and financing flexibility rather than product profitability.
• Revenue remains modest relative to expenses, so this is still primarily a development-stage biotech story.
• The quarter included a large amount of investing activity in marketable securities, which is typical for a company managing a large cash portfolio.
• Crinetics posted an operating loss of $140.4 million in Q1 2026, showing that spending remains far above revenue.
• Net cash from operating activities was negative $124.7 million, underscoring ongoing cash burn from operations.

Trend over the last several years: Crinetics has steadily grown its cash and investment balance through capital raises and investment management, but profitability has not improved in a durable way. Revenue has ticked up from near-zero levels, yet quarterly operating expenses have also climbed, especially R&D and SG&A.

For example, quarterly R&D expense rose from roughly $53.3 million in Q1 2024 to $100.1 million in Q1 2026, while SG&A increased from $20.8 million to $50.8 million over the same period. That tells investors the company is investing aggressively in development and commercialization, but it also means losses remain large.

Balance sheet trend: The company’s cash position has actually fluctuated quite a bit quarter to quarter, but it remains exceptionally strong overall. At the end of Q1 2024, Crinetics had about $901 million in cash and short-term investments. By Q3 2024, that had climbed to roughly $863 million, then rose again to more than $1.09 billion at Q4 2025 and $1.29 billion in Q1 2026. This suggests the company has been successful in preserving a very healthy war chest despite ongoing losses.

Cash flow remains the key issue: The business is still consuming cash from operations. Q1 2026 operating cash flow was negative $124.7 million, compared with negative $88.5 million in Q1 2025 and negative $52.9 million in Q1 2024. So while the balance sheet is strong today, investors should expect continued cash burn as long as the pipeline remains in development.

Bottom line: Crinetics looks financially stable for now because of its large cash reserve, but it is not close to profitability. The stock’s long-term investment case will depend on whether management can convert its R&D spending into meaningful commercial revenue before cash burn becomes a bigger concern.